Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction: Validation Against Invasive Coronary Physiology.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
10 2019
Historique:
received: 08 10 2018
revised: 03 12 2018
accepted: 06 12 2018
pubmed: 18 2 2019
medline: 14 7 2020
entrez: 18 2 2019
Statut: ppublish

Résumé

This study sought to assess the performance of cardiovascular magnetic resonance (CMR) myocardial perfusion mapping against invasive coronary physiology reference standards for detecting coronary artery disease (CAD, defined by fractional flow reserve [FFR] ≤0.80), microvascular dysfunction (MVD) (defined by index of microcirculatory resistance [IMR] ≥25) and the ability to differentiate between the two. Differentiation of epicardial (CAD) and MVD in patients with stable angina remains challenging. Automated in-line CMR perfusion mapping enables quantification of myocardial blood flow (MBF) to be performed rapidly within a clinical workflow. Fifty patients with stable angina and 15 healthy volunteers underwent adenosine stress CMR at 1.5T with quantification of MBF and myocardial perfusion reserve (MPR). FFR and IMR were measured in 101 coronary arteries during subsequent angiography. Twenty-seven patients had obstructive CAD and 23 had nonobstructed arteries (7 normal IMR, 16 abnormal IMR). FFR positive (epicardial stenosis) areas had significantly lower stress MBF (1.47 ± 0.48 ml/g/min) and MPR (1.75 ± 0.60) than FFR-negative IMR-positive (MVD) areas (stress MBF: 2.10 ± 0.35 ml/g/min; MPR: 2.41 ± 0.79) and normal areas (stress MBF: 2.47 ± 0.50 ml/g/min; MPR: 2.94 ± 0.81). Stress MBF ≤1.94 ml/g/min accurately detected obstructive CAD on a regional basis (area under the curve: 0.90; p < 0.001). In patients without regional perfusion defects, global stress MBF <1.82 ml/g/min accurately discriminated between obstructive 3-vessel disease and MVD (area under the curve: 0.94; p < 0.001). This novel automated pixel-wise perfusion mapping technique can be used to detect physiologically significant CAD defined by FFR, MVD defined by IMR, and to differentiate MVD from multivessel coronary disease. A CMR-based diagnostic algorithm using perfusion mapping for detection of epicardial disease and MVD warrants further clinical validation.

Sections du résumé

OBJECTIVES
This study sought to assess the performance of cardiovascular magnetic resonance (CMR) myocardial perfusion mapping against invasive coronary physiology reference standards for detecting coronary artery disease (CAD, defined by fractional flow reserve [FFR] ≤0.80), microvascular dysfunction (MVD) (defined by index of microcirculatory resistance [IMR] ≥25) and the ability to differentiate between the two.
BACKGROUND
Differentiation of epicardial (CAD) and MVD in patients with stable angina remains challenging. Automated in-line CMR perfusion mapping enables quantification of myocardial blood flow (MBF) to be performed rapidly within a clinical workflow.
METHODS
Fifty patients with stable angina and 15 healthy volunteers underwent adenosine stress CMR at 1.5T with quantification of MBF and myocardial perfusion reserve (MPR). FFR and IMR were measured in 101 coronary arteries during subsequent angiography.
RESULTS
Twenty-seven patients had obstructive CAD and 23 had nonobstructed arteries (7 normal IMR, 16 abnormal IMR). FFR positive (epicardial stenosis) areas had significantly lower stress MBF (1.47 ± 0.48 ml/g/min) and MPR (1.75 ± 0.60) than FFR-negative IMR-positive (MVD) areas (stress MBF: 2.10 ± 0.35 ml/g/min; MPR: 2.41 ± 0.79) and normal areas (stress MBF: 2.47 ± 0.50 ml/g/min; MPR: 2.94 ± 0.81). Stress MBF ≤1.94 ml/g/min accurately detected obstructive CAD on a regional basis (area under the curve: 0.90; p < 0.001). In patients without regional perfusion defects, global stress MBF <1.82 ml/g/min accurately discriminated between obstructive 3-vessel disease and MVD (area under the curve: 0.94; p < 0.001).
CONCLUSIONS
This novel automated pixel-wise perfusion mapping technique can be used to detect physiologically significant CAD defined by FFR, MVD defined by IMR, and to differentiate MVD from multivessel coronary disease. A CMR-based diagnostic algorithm using perfusion mapping for detection of epicardial disease and MVD warrants further clinical validation.

Identifiants

pubmed: 30772231
pii: S1936-878X(19)30064-6
doi: 10.1016/j.jcmg.2018.12.022
pmc: PMC8414332
mid: NIHMS1732436
pii:
doi:

Substances chimiques

Vasodilator Agents 0
Adenosine K72T3FS567

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1958-1969

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : ZIA HL006214
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 HL999999
Pays : United States
Organisme : British Heart Foundation
ID : RG/16/1/32092
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/21/33447
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Références

Circulation. 1996 Oct 15;94(8):1842-9
pubmed: 8873658
JACC Cardiovasc Imaging. 2018 May;11(5):697-707
pubmed: 29454767
Circ Cardiovasc Interv. 2015 Nov;8(11):e002857
pubmed: 26499500
J Cardiovasc Magn Reson. 2017 Apr 7;19(1):43
pubmed: 28385161
Circulation. 2014 Apr 29;129(17):1723-30
pubmed: 24573349
J Am Coll Cardiol. 2008 Aug 19;52(8):636-43
pubmed: 18702967
J Cardiovasc Magn Reson. 2014 Feb 24;16:19
pubmed: 24565078
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
J Cardiovasc Magn Reson. 2018 Jul 9;20(1):48
pubmed: 29983119
JACC Cardiovasc Imaging. 2016 Apr;9(4):465-82
pubmed: 27056165
Circ Cardiovasc Interv. 2017 Dec;10(12):
pubmed: 29222132
Circulation. 1992 Jul;86(1):179-86
pubmed: 1617771
Eur Heart J Cardiovasc Imaging. 2014 Jun;15(6):701-8
pubmed: 24493156
JAMA. 2016 Sep 13;316(10):1051-60
pubmed: 27570866
J Nucl Med. 2007 Feb;48(2):175-81
pubmed: 17268011
J Cardiovasc Magn Reson. 2016 Sep 13;18(1):57
pubmed: 27624746
PLoS One. 2014 Apr 04;9(4):e93170
pubmed: 24705387
J Am Coll Cardiol. 2010 Aug 10;56(7):561-9
pubmed: 20688211
J Am Coll Cardiol. 2018 Mar 6;71(9):969-979
pubmed: 29495996
Eur Heart J. 2013 Mar;34(10):775-81
pubmed: 22390914
J Cardiovasc Magn Reson. 2017 Nov 27;19(1):92
pubmed: 29178905
Eur Heart J. 2012 Mar;33(6):734-44
pubmed: 21911339
Circulation. 2015 Mar 24;131(12):1054-60
pubmed: 25712205
J Am Coll Cardiol. 2011 Jan 4;57(1):70-5
pubmed: 21185504
N Engl J Med. 2010 Mar 11;362(10):886-95
pubmed: 20220183
JACC Cardiovasc Imaging. 2013 May;6(5):600-9
pubmed: 23582358
AJR Am J Roentgenol. 2010 Aug;195(2):356-62
pubmed: 20651190
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
N Engl J Med. 2012 Sep 13;367(11):991-1001
pubmed: 22924638
J Cardiovasc Magn Reson. 2017 Oct 19;19(1):78
pubmed: 29047385

Auteurs

Tushar Kotecha (T)

Institute of Cardiovascular Science, University College London, United Kingdom; Royal Free Hospital, London, United Kingdom.

Ana Martinez-Naharro (A)

Royal Free Hospital, London, United Kingdom; Division of Medicine, University College London, United Kingdom.

Michele Boldrini (M)

Division of Medicine, University College London, United Kingdom.

Daniel Knight (D)

Institute of Cardiovascular Science, University College London, United Kingdom; Royal Free Hospital, London, United Kingdom.

Philip Hawkins (P)

Royal Free Hospital, London, United Kingdom; Division of Medicine, University College London, United Kingdom.

Sundeep Kalra (S)

Royal Free Hospital, London, United Kingdom.

Deven Patel (D)

Royal Free Hospital, London, United Kingdom.

Gerry Coghlan (G)

Royal Free Hospital, London, United Kingdom.

James Moon (J)

Institute of Cardiovascular Science, University College London, United Kingdom; Barts Heart Centre, London, United Kingdom.

Sven Plein (S)

Institute of Cardiovascular and Metabolic Medicine, University of Leeds, United Kingdom.

Tim Lockie (T)

Royal Free Hospital, London, United Kingdom.

Roby Rakhit (R)

Institute of Cardiovascular Science, University College London, United Kingdom; Royal Free Hospital, London, United Kingdom.

Niket Patel (N)

Institute of Cardiovascular Science, University College London, United Kingdom; Royal Free Hospital, London, United Kingdom.

Hui Xue (H)

National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland.

Peter Kellman (P)

National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland.

Marianna Fontana (M)

Royal Free Hospital, London, United Kingdom; Division of Medicine, University College London, United Kingdom. Electronic address: m.fontana@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH